中文产业新闻评分34Chinese source
降低46%肝病风险！再生元全球首创CIDEB靶向siRNA疗法ALN-CIDEB启动III期临床
降低46%肝病风险！再生元全球首创新药启动III期临床，多家国内药企已布局
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
降低46%肝病风险！再生元全球首创新药启动III期临床，多家国内药企已布局
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.